A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma
Open Access
- 12 October 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-12
Abstract
Background: This study aimed to develop a reliable immune signature based on B-cell proportion to predict the prognosis and benefit of immunotherapy in LUAD. Methods: The proportion of immune cells in the TCGA-LUAD dataset was estimated using MCP-counter. The Least Absolute Shrinkage and Selector Operation was used to identify a prognostic signature and validated in an independent cohort. We used quantitative reverse transcription-polymerase chain reaction (qRT-PCR) data and formalin-fixed paraffin-embedded (FFPE) specimens immunohistochemistry to illustrate the correlation between prognostic signature and leukocyte migration. Results: We found that the relative abundance of B lineage positively correlated with overall survival. Then, we identified a 13-gene risk-score prognostic signature based on B lineage abundance in the testing cohort and validated it in a cohort from the GEO dataset. This model remained strongly predictive of prognoses across clinical subgroups. Further analysis revealed that patients with a low-risk score were characterized by B-cell activation and leukocyte migration, which was also confirmed in FFPE specimens by qRT-PCR and immunohistochemistry. Finally, this immune signature was an independent prognostic factor in the composite nomogram of clinical characteristics. Conclusions: In conclusion, the 13-gene immune signature based on B-cell proportion may serve as a powerful prognostic tool in LUAD.Keywords
This publication has 35 references indexed in Scilit:
- The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2016
- Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer DevelopmentCancer Discovery, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- RNA-binding protein hnRNPLL regulates mRNA splicing and stability during B-cell to plasma-cell differentiationProceedings of the National Academy of Sciences, 2015
- Tertiary lymphoid structures in cancer and beyondTrends in Immunology, 2014
- Ectopic lymphoid-like structures in infection, cancer and autoimmunityNature Reviews Immunology, 2014
- Influence of tumour micro-environment heterogeneity on therapeutic responseNature, 2013
- Prognostic Impact of Cancer-Associated Stromal Cells in Patients With Stage I Lung AdenocarcinomaChest, 2012
- Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancerProceedings of the National Academy of Sciences, 2011
- B-cell and plasma-cell splicing differences: A potential role in regulated immunoglobulin RNA processingRNA, 2003